Cargando…
Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
Autores principales: | Chanan-Khan, A, Egyed, M, Robak, T, Martinelli de Oliveira, F A, Echeveste, M A, Dolan, S, Desjardins, P, Blonski, J Z, Mei, J, Golany, N, Zhang, J, Gribben, J G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420789/ https://www.ncbi.nlm.nih.gov/pubmed/28140392 http://dx.doi.org/10.1038/leu.2017.47 |
Ejemplares similares
-
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2019) -
Rapidly progressive renal failure due to chronic lymphocytic leukemia - Response to chlorambucil
por: Junglee, N. A., et al.
Publicado: (2012) -
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
por: Casado, Luis Felipe, et al.
Publicado: (2016) -
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
por: Bühler, A, et al.
Publicado: (2016) -
Lenalidomide and Chronic Lymphocytic Leukemia
por: González-Rodríguez, Ana Pilar, et al.
Publicado: (2013)